INTRODUCTION
Tumor necrosis factor (TNF) is an inflammatory cytokine that exerts multiple biological activities on target tissues, including cell survival, cell proliferation, and cell death. The consequence of cellular exposure to TNF reflects the opposing actions of signaling pathways that are activated by cell surface TNF receptors, including nuclear factor kB (NF-kB), mitogen-activated protein (MAP) kinases, and caspases (Chen and Goeddel, 2002) .
The type 1 TNF receptor (TNFR1) mediates signal transduction by recruiting proteins that assemble on the cytoplasmic tail of the receptor, including the scaffold protein TRADD, the protein kinase RIP1, and TRAF2/5 adaptor proteins (Micheau and Tschopp, 2003) . This complex signals the activation of NF-kB and MAP kinase pathways, is transiently assembled, and subsequently dissociates from the cytoplasmic tail of the receptor. A second complex is then formed by the TRADD scaffold protein together with RIP1, the adaptor protein FADD, cFLIP, and procaspase 8 (Micheau and Tschopp, 2003) . This complex activates caspase 8 and promotes apoptosis. The strength of caspase 8 signaling is regulated, in part, by the level of NF-kB-dependent expression of the pseudocaspase cFLIP that functions as an inhibitor of pro-caspase 8 activation (Thome and Tschopp, 2001 ). TNF-a-induced caspase 8 activation can also be mediated after mitochondrial outer membrane permeabilization by Smac-induced degradation of cIAP1/2, CYLD-dependent release of RIP1 from the cytoplasmic tail of TNFR1, and the subsequent formation of a RIP1 complex with FADD and caspase 8 (Wang et al., 2008) .
The type 2 TNF receptor (TNFR2) functions together with TNFR1, in part, by recruiting the E3 ligase c-IAP1 that can ubiquitinate and degrade c-IAP2 and the adaptor protein TRAF2 (Chan and Lenardo, 2000; Conze et al., 2005; Fotin-Mleczek et al., 2002; Li et al., 2002; Wu et al., 2005) . TNFR2 potentiates TNFR1-stimulated cell death by blocking TRAF2-mediated activation of antiapoptotic signaling by NF-kB and MAP kinases. Indeed, cell surface TNF-a, which binds both TNFR1 and TNFR2, is a more potent inducer of cell death than soluble TNF-a, which preferentially binds TNFR1 (Eissner et al., 1995; Grell et al., 1995 Grell et al., , 1998 .
JNK represents one of the MAP kinases activated by TNFR1. The mechanism of JNK regulation is mediated by the TRAF2/5 adaptor proteins that cause ubiquitin-dependent activation of the MAP kinase kinase kinase TAK1 that phosphorylates and activates the MAP kinase kinase MKK7, which, in turn, phosphorylates and activates JNK (Adhikari et al., 2007; Sato et al., 2005; Shim et al., 2005; Tournier et al., 2001 ). This TRAF-mediated activation of JNK is transient. A sustained phase of JNK activation, observed at later times, might be mediated by a TNF-induced complex of TRADD, RIP1, NOX1, and RAC1 (Kim et al., 2007) that causes accumulation of reactive oxygen species (ROS) and activation of the JNK pathway (Sakon et al., 2003) by increasing ASK1 activity (Tobiume et al., 2001 ) and decreasing phosphatase activity (Kamata et al., 2005) . This second and sustained phase of TNF-stimulated JNK activation is negatively regulated by NF-kB (De Smaele et al., 2001; Reuther-Madrid et al., 2002; Tang et al., 2001 ) by suppression of ROS accumulation (Pham et al., 2004; Sakon et al., 2003) .
The two phases of TNF-stimulated JNK activation appear to mediate different cellular responses . The initial transient phase of TRAF-mediated JNK activation might signal cell survival and the later sustained phase of JNK activation might contribute to ROS-induced cell death (Ventura et al., 2004) . The exact role of TNF-stimulated JNK in the regulation of cell survival and/or death has been controversial (Varfolomeev and Ashkenazi, 2004) . Studies of cultured fibroblasts demonstrate that compound mutation of the Jnk1 and Jnk2 genes does not prevent TNF-stimulated apoptosis , but JNK1/2-deficient fibroblasts do exhibit defects in the TNF-induced accumulation of cytotoxic ROS (Ventura et al., 2004) . However, these studies employed artificial cell culture conditions (inhibition of transcription, translation, or NF-kB) to enable TNF-stimulated cell death. These procedures were necessary because treatment of wild-type fibroblasts with TNF alone does not cause cell death. This analysis illustrates the need for better methods to study TNF-induced cell death that are not dependent on the use of artificial cell culture conditions.
It has been reported that TNF-induced cell death can be studied using mouse models of hepatitis. For example, treatment of mice with the lectin concanavalin A (Con A) causes fulminant hepatitis in wild-type mice (Tiegs et al., 1992) . Liver cell death in this model is TNF dependent because Con A causes greatly reduced hepatitis in both Tnfr1 À/À and Tnfr2 À/À mice (Kusters et al., 1997; Maeda et al., 2003) . Furthermore, Con A-induced hepatitis requires membrane-bound TNF-a, but not soluble TNF-a (Kusters et al., 1997) . This form of hepatitis has been reported to require JNK (Chang et al., 2006; Kamata et al., 2005; Maeda et al., 2003) . The mechanism of JNK signaling might be mediated by phosphorylation and activation of the E3 ligase Itch that can ubiquitinate and degrade the caspase 8 antagonist cFLIP (Chang et al., 2006) . This function of JNK in TNF-stimulated cell death is consistent with several reports that have implicated an essential role of JNK in TNF-stimulated apoptosis of tumor cell lines (Deng et al., 2003; Verheij et al., 1996) , fibroblasts (Dietrich et al., 2004; Liu et al., 2004) , and hepatocytes (Chang et al., 2006; Kamata et al., 2005; Maeda et al., 2003; Wang et al., 2006) , but is inconsistent with other reports that suggest a nonessential role of JNK in TNF-stimulated cell death (Hochedlinger et al., 2002; Lamb et al., 2003; Liedtke et al., 2002; Liu et al., 1996; Natoli et al., 1997) . The purpose of this study was to examine the role of JNK in TNF-mediated hepatitis using compound mutant mice with defects in both of the ubiquitously expressed genes that encode JNK isoforms. Our analysis demonstrates that JNK is essential for hepatitis. We show that JNK in hematopoietic cells is critically required for TNF-a expression and that JNK is not required for TNF-a-stimulated cell death during the development of hepatitis.
RESULTS

Examination of Hepatitis in Mice Deficient of JNK1 or JNK2
It has been reported that Jnk1 À/À mice and Jnk2 À/À mice exhibit a major defect in Con A-induced hepatitis (Maeda et al., 2003) , although subsequent studies have reported a primary role played by JNK1 (Chang et al., 2006; Kamata et al., 2005) . We tested the effect of Con A-induced hepatitis on wild-type, Jnk1
, and Jnk2 À/À mice (see Figure S1 available online).
Con A caused similar hepatic damage in wild-type and JNKknockout mice ( Figures S1A and S2A ). Serum transaminase activity, a hallmark of hepatic injury, was modestly reduced in both Jnk1 À/À mice and Jnk2 À/À mice compared with wild-type mice, but the differences were not statistically significant ( Figure S1B ). The effects of Con A on hepatic injury are thought to be mediated by induced cytokine expression. Similar amounts of serum cytokines were detected in the wild-type and knockout mice, although a selective loss of interleukin-1 expression was found in Jnk1 À/À mice ( Figure S1C ). Figure S3B ), and decreased expression of serum cytokines, including TNF-a and interferong (IFN-g) ( Figure S3C ).
Examination of Hepatitis in Compound Mutant
Our analysis of hepatitis in Jnk1 À/À mice and Jnk2 À/À mice indicated that JNK1 and JNK2 might contribute to the disease process ( Figures S1-S3 ). However, the roles of JNK1 and JNK2 are unclear because we found that Jnk1 À/À mice and
Jnk2
À/À mice did not demonstrate defects in Con A-induced hepatitis ( Figure S1 ). These observations suggested the possibility that JNK1 and JNK2 play redundant roles during the development of hepatitis ( Figure S4 ). To test this hypothesis, we examined the effect of Con A in mice with compound disruption of both the Jnk1 and Jnk2 genes. Because Jnk1 À/À Jnk2 À/À mice die during early embryonic development (Kuan et al., 1999) , we employed a conditional gene ablation strategy. Efficient deletion of floxed alleles in both the liver and hematopoietic cells can be achieved in Mx1-Cre transgenic mice when these mice are treated with polyinosinic-polycytidylic acid (poly-IC) (Kuhn et al., 1995) . We therefore treated Mx1-Cre ) was confirmed by polymerase chain reaction (PCR) analysis of genomic DNA. JNK protein was not detected in the liver of the compound mutant mice by immunoblot analysis ( Figure 1A ). Treatment of these mice with Con A demonstrated that the JNK1/2-deficient mice exhibited strong protection against hepatitis when examined by histological analysis of liver sections (Figures 1B and S2C) or measurement of serum transaminase activity ( Figure 1C ). The JNK1/2-deficient mice also exhibited reduced mortality compared with control mice in response to the Con A challenge ( Figure S5A ). Studies of hepatic gene expression demonstrated that the Jnk1 D/D Jnk2 À/À liver exhibited defects in the Con Ainduced expression of several AP1-related genes ( Figure 1D ). This observation suggested that the Jnk1 D/D Jnk2 À/À liver might exhibit profound defects in AP1-dependent gene expression. Indeed, expression of the AP1 target gene Tnfa was profoundly reduced in the liver of Con A-treated JNK1/2-deficient mice ( Figure 1D ). This loss of TNF-a expression was confirmed by measurement of the concentration of serum cytokines. Con A induced the expression of many cytokines in the serum of control mice, but JNK1/2-deficient mice exhibited major defects in serum cytokine expression, including TNF-a ( Figure 2 ).
The protection of Mx1-Cre + Jnk1 f/f Jnk2 À/À mice against hepatitis (Figures 1 and S2) was confirmed by studies using the LPS model of hepatitis. JNK1/2 deficiency prevented LPS-induced hepatic damage detected by histological analysis of liver sections (Figures S2D and S6A) , and measurement of serum transaminase activity ( Figure S6B ). Decreased expression of AP1-related genes and Tnfa mRNA in the liver ( Figure S6D ) and decreased amounts of serum TNF-a were also detected in the JNK1/2-deficient mice ( Figure S6E ). The JNK1/2-deficient mice also exhibited reduced mortality compared with control mice in the response to LPS challenge ( Figure S7A ). Together, these ) were aged 4 weeks and then treated intravenously (8 hr) with Con A or solvent (saline). Liver extracts were examined by immunoblot analysis using antibodies to JNK1/2, cFLIP, and a-tubulin. (B) Representative hematoxylin and eosin (H&E)-stained liver sections prepared from control and JNK1/2-deficient mice treated (8 hr) with Con A or solvent (saline) are presented. The amount of liver damage was quantitated ( Figure S2C ). (C) Serum transaminase activity in control and JNK1/2-deficient mice treated (8 hr) with Con A or solvent (saline) was measured (mean ± SD; n = 6). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.01). (D) RNA was isolated from the liver of control and JNK1/2-deficient mice treated (8 hr) with Con A or solvent (saline). The expression of mRNA was measured by quantitative real-time PCR assays. The mRNA expression was normalized to the amount of Gapdh mRNA and presented as the mean ± SD (n = 6). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.01).
data indicate that compound deficiency of both JNK1 and JNK2 caused strong protection against two different models of hepatitis that are induced by treatment of mice with Con A or LPS, respectively.
JNK Deficiency in Hepatocytes Does Not Protect Mice against Hepatitis
The observation that compound mutation of Jnk1 and Jnk2 causes protection against both Con A-and LPS-induced hepatitis (Figures 1, S2 , and S6) suggested that JNK1 and JNK2 play redundant roles during progression of the disease process. It has been proposed that these models of hepatitis are mediated by TNF-a-induced and JNK-mediated phosphorylation and activation of the E3 ligase Itch and the subsequent ubiquitin-mediated degradation of the caspase 8 antagonist cFLIP in hepatocytes (Chang et al., 2006) . To test this hypothesis, we examined cFLIP in control and JNK1/2-deficient liver of mice treated with Con A; no changes in cFLIP expression were detected ( Figure 1A ). In contrast, treatment with LPS did cause cFLIP degradation, but this degradation of cFLIP was JNK independent ( Figure S6C ). The observation that LPS, but not Con A, caused cFLIP degradation might reflect the more potent effects of LPS on hepatitis compared with Con A. Together, these observations indicate that JNK-mediated cFLIP degradation is not required for murine models of hepatitis caused by Con A or LPS.
To test the role of JNK in hepatocytes, we examined the effect of hepatocyte-specific JNK deficiency using Alb-Cre transgenic mice. Immunoblot analysis of liver extracts prepared from control (Alb-Cre + ) mice and JNK-deficient (Alb-
mice demonstrated that very low amounts of JNK were detected in JNK-deficient liver ( Figure 3A ). The presence of low levels of JNK in the Alb-Cre deleted mice is consistent with the finding that the Alb-Cre transgene is selectively expressed in hepatocytes, but not in other liver cell-types, including stellate cells, endothelial cells, NK cells, NKT cells, and Kupffer cells (Postic et al., 1999) . Control studies demonstrated that hepatocytespecific JNK1/2 deficiency caused markedly reduced hepatic JNK activity (monitored by measurement of phospho-Ser 73 c-Jun) in mice treated with Con A or LPS (Figures 4B and S8B) . Treatment with Con A caused similar hepatic damage in control and hepatocyte-specific JNK1/2-deficient mice (Figures 3B and S2C) . No differences in TUNEL staining of liver sections of the control and JNK1/2-deficient mice were detected (Figure 3C) . Similarly, no significant difference in serum transaminase activity between the control and JNK1/2-deficient mice was observed ( Figure 3D ). The JNK1/2-deficient mice and control mice also exhibited similar mortality in response to the Con A challenge ( Figure S5B ). Gene expression analysis in JNK1/2-deficient mice did not indicate a consistent loss of AP1-related gene expression, p53-pathway-related gene expression, or Tnfa mRNA expression in the liver compared with control mice ( Figure 3E) . Measurement of serum cytokines demonstrated that JNK1/2 deficiency in hepatocytes did not cause decreased expression of TNF-a or other cytokines examined in Con A-treated mice ( Figure 4A ).
Our analysis of Con A-treated mice demonstrated that JNK expression in hepatocytes is not required for the development of hepatitis (Figures 3, S2C , and S5B). This conclusion was confirmed by studies of LPS-induced hepatitis (Figures 5 and S7A) . LPS caused similar hepatic damage in control and hepatocyte-specific JNK1/2-deficient mice that was detected by histological analysis of liver sections ( Figure 5A ), TUNEL labeling of apoptotic cells in liver sections ( Figure 5A ), and serum transaminase activity ( Figure 5B ). Furthermore, JNK1/2 deficiency in hepatocytes did not cause changes in the LPS-induced expression of AP1-related genes, p53-pathway-related genes, or Tnfa mRNA in liver ( Figure 5E ). LPS also caused a similar increase in the serum concentration of TNF-a in mice with JNK1/2-deficient hepatocytes and control mice ( Figure 5C and ) were aged 4 weeks and then treated intravenously with Con A. The amount of serum cytokines after treatment with Con A was measured by ELISA (mean ± SD; n = 7). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.05; **p < 0.01). S8A). Moreover, cFLIP expression in LPS-treated mice was not affected by hepatocyte-specific deficiency of JNK1/2 ( Figure 5D ).
These data demonstrate that there is no critical role of JNK in hepatocytes for the development of hepatitis, including treatment with Con A or LPS (Figures 3, 5, S2C, and S2D ). This finding contrasts with conclusions drawn from previous studies that have suggested an essential role of JNK in hepatocytes for Con A-induced hepatitis (Chang et al., 2006; Kamata et al., 2005; Maeda et al., 2003) .
JNK Is Required for TNF-a Expression but Is Not Required for TNF-a-Induced Hepatic Damage
The requirement of JNK for hepatocyte death during the development of hepatitis (Figures 1 and S6) is not mediated by the function of JNK in hepatocytes (Figures 3-5) . These data suggest that JNK plays a non-cell autonomous essential role. We considered several possible mechanisms. The simplest possibility was a requirement of JNK for Con A-and LPS-induced expression of inflammatory cytokines by cells that are not hepatocytes. This is consistent with the finding that Mx1-Cre + JNK1/2-deficient mice, which are protected against Con A-and LPS-induced hepatitis (Figures 1, S2C , S2D, and S6), exhibit defects in the expression of inflammatory cytokines, including TNF-a ( Figures 1D, 2, S6D , and S6E). In contrast, hepatocyte-specific JNK1/2 deficiency did not protect against hepatitis and did not cause marked changes in inflammatory cytokine expression ( Figures 4A, 5C , 5E, and S8A).
To test whether JNK is required for inflammatory cytokine expression, we prepared in vitro primary cultures of bonemarrow-derived macrophages from poly-IC-treated control (Mx1-Cre) and JNK1/2-deficient mice (Mx1- (D) Serum transaminase activity in control and JNK-deficient mice after treatment (8 hr) with Con A or solvent (saline) was measured (mean ± SD; n = 6). No statistically significant differences between wild-type and JNK1/2-deficient mice were detected. (E) RNA was isolated from the liver of control and JNK-deficient mice after treatment (8 hr) with ConA or solvent (saline). The expression of mRNA was measured by quantitative RT-PCR assays (Taqman ª ). The mRNA expression was normalized to the amount of Gapdh mRNA and presented as the mean ± SD (n = 6). No statistically significant differences between wild-type and JNK1/2-deficient mice were detected.
No JNK was detected in the JNK1/2-deficient macrophages by immunoblot analysis ( Figure 6A ). Treatment with Con A demonstrated increased concentrations of cytokines (TNF-a and IL-6) in the culture medium of control macrophages ( Figure 6B ). The amount of these cytokines in the culture medium of JNK1/2-deficient macrophages was markedly suppressed ( Figure 6B ). In contrast, JNK1/2 deficiency did not alter the expression of IL-10 ( Figure 6B ). Similarly, JNK1/2-deficient T cells exhibited defects in Con A-stimulated expression of TNF-a ( Figure S4 ).
Together, these data demonstrate that JNK1/2 is required for the expression of the inflammatory cytokine TNF-a. If the essential role of JNK in hepatitis (Figures 1 and S6 ) reflects a requirement of JNK for the expression of inflammatory cytokines (Figures 2, 6B, and S4 ), then it would be predicted that the defect in hepatitis caused by JNK deficiency would be complemented by treatment of mice with TNF-a. We detected no significant difference between control and JNK-deficient mice in TNF-a-induced serum transaminase activity ( Figure 6E ) and mortality ( Figure S7B ). Immunoblot analysis demonstrated that TNF-a caused similar caspase 3 activation and PARP cleavage in the liver of control mice, Mx1-Cre + JNK1/2-deficient mice,
and Alb-Cre + JNK1/2-deficient mice ( Figures 6C and 6D ). These data confirm that the essential role of JNK1/2 for hepatitis is mediated by a requirement of JNK1/2 for inflammatory cytokine expression, including TNF-a, and does not reflect a role for JNK in TNF-a-stimulated hepatocyte death.
The pro-death role of inflammatory cytokines in hepatitis is opposed by factors that sustain cell survival. One example is the role of IL-22 to activate the Stat3 and AKT signaling pathways in hepatocytes. Indeed, loss of IL-22 expression increases Con ) were treated intravenously with Con A. The amount of serum cytokines (IL-1, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, GM-CSF, TNF-a, and IFN-g) after treatment with Con A was measured by ELISA (mean ± SD; n = 8). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.05). (B) The amount of total and phospho-c-Jun, ERK, p38 MAPK, and AKT in liver extracts at 8 hr after treatment of mice with Con A or saline was measured by multiplexed ELISA (mean ± SD; n = 5). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.01).
A-induced hepatitis (Zenewicz et al., 2007) . Altered expression of IL-22 might therefore contribute to the effects of JNK1/2-deficiency on Con A-induced hepatitis. However, no significant difference in IL-22 expression was detected between control and JNK1/ 2-deficient mice ( Figure S9 ). Together, these data indicate that IL-22 does not mediate the effects of JNK1/2 deficiency on hepatitis.
JNK Is Required for TNF Expression by Hematopoietic Cells
Hematopoietic cells represent one source of the inflammatory cytokines that might cause hepatitis after treatment with Con A or LPS (Dong et al., 2007) . To test the role of hematopoietic cells, we constructed radiation chimeras by transplantation of control (Mx1-Cre No statistically significant differences between wild-type and JNK1/2-deficient mice were detected.
Jnk2
+/+ C57BL/6J bone marrow cells, displayed similar numbers of CD45.1 and CD45.2 peripheral blood leukocytes 6 months after transplantation ( Figure 7A ). Together, these data demonstrate that JNK1 and JNK2 are not essential for the repopulation of the hematopoietic compartment after bone marrow transplantation.
Radiation chimeras with Jnk1
hematopoietic cells in the blood were identified by quantitative real-time PCR (RT-PCR) analysis of Jnk1 mRNA expression ( Figure 7B ), by PCR analysis of genomic DNA ( Figure 7C) , and by immunoblot analysis using a JNK antibody ( Figure 7D ). Flow cytometry analysis of splenocytes demonstrated similar numbers of CD4 T cells, CD8 T cells, and B cells in mice reconstituted with control and JNK1/2-deficient bone marrow ( Figure 7E ). Long-lived resident hematopoietic cells in the liver are slowly replaced after bone marrow transplantation; therefore, we examined mice 6 months after transplantation (Alves-Guerra et al.,
2003). Treatment of the radiation chimeras transplanted with
Jnk1
+/+ Jnk2 +/+ bone marrow demonstrated that treatment with Con A caused hepatic damage, including increased amounts of serum transaminase activity ( Figure 7F ). In contrast, radiation chimeras transplanted with Jnk1 D/D Jnk2 À/À bone marrow were protected against hepatic damage caused by Con A, including reduced amounts of serum transaminase activity ( Figure 7F ), and decreased amounts of Tnfa mRNA in the liver and TNF-a protein expression in blood ( Figure 7G ). Together, these data confirm that JNK1/2 in hematopoietic cells is required for the development of hepatitis.
DISCUSSION
The results of our study demonstrate that JNK is essential for the development of hepatitis in mouse models. This finding is examined by immunoblot analysis using antibodies to JNK1/2 and a-tubulin. The macrophages were treated with Con A and cytokines in the culture medium were measured by ELISA (mean ± SD; n = 7). Statistically significant differences between wild-type and JNK1/2-deficient mice are indicated (*p < 0.01).
(C,D) Poly-IC-treated control mice (Mx1-Cre + ) and JNK-deficient mice (Jnk1 f/f Jnk2 À/À Mx1-Cre + ) (C) or control mice (Alb-Cre + ) and mice with hepatocyte-specific
were treated intravenously (8 hr) with TNF-a plus GalN or solvent (saline). Liver extracts were examined by immunoblot analysis using antibodies to caspase-cleaved PARP, cleaved caspase 3, and a-tubulin. (E) Serum transaminase activity in control and JNK1/2-deficient mice after treatment (8 hr) with LPS/GalN or solvent (saline) was measured (mean ± SD; n = 6). No statistically significant differences between wild-type and JNK1/2-deficient mice were detected. important because of the implication that JNK might be a useful target for drug therapy for some forms of hepatitis in humans. Indeed, drugs with specificity for JNK are currently under clinical development (Manning and Davis, 2003) . However, an unexpected finding of this study was that JNK appears to play no role in hepatocytes, but JNK is essential for TNF-a expression by hematopoietic cells. Therefore, measurement of TNF-a might serve as a relevant biomarker that is useful for monitoring the efficacy of JNK inhibition in protocols using JNK inhibitors in humans.
JNK Is Not Essential for TNF-Stimulated Cell Death of Hepatocytes
It has previously been reported that JNK is required for TNFa-stimulated cell death. Thus, partial JNK deficiency caused by disruption of the Jnk1 or Jnk2 genes has been reported to reduce TNF-stimulated apoptosis by unknown mechanisms (Dietrich et al., 2004; Kamata et al., 2005; Liu et al., 2004; Maeda et al., 2003; Wang et al., 2006) . Furthermore, partial JNK deficiency has been reported to cause reduced JNK-mediated phosphorylation of the E3 ligase Itch, failure to ubiquitinate and degrade the , and Jnk1 D alleles (C). Splenocytes were examined by immunoblot analysis using antibodies to JNK1/2 and ERK1/2 (D) and subpopulations of splenocytes were examined by flow cytometry (E). (F) Mice at 6 months after transplantation were treated intravenously (8 hr) with Con A or solvent (saline) and serum transaminase activity (ALT and AST) was measured (mean ± SD; n = 6). Statistically significant differences between mice transplanted with control and JNK1/2-deficient bone marrow are indicated (*p < 0.01).
(G) Mice at 6 months after transplantation were treated intravenously with Con A or solvent (saline). The expression of Gapdh, and Tnfa mRNA in the liver was measured by quantitative RT-PCR assays (Taqman ª ) at 8 hr after injection (left panel). The mRNA expression in each sample was normalized to the amount of Gapdh mRNA and presented as the mean ± SD (n = 6). The concentration of TNF-a in the blood was measured at 1 hr after injection by ELISA and is presented as the mean ± SD (n = 7) (right panel). Statistically significant differences between mice transplanted with control and JNK1/2-deficient bone marrow are indicated (*p < 0.01).
caspase 8 antagonist cFLIP, and protection against TNF-stimulated cell death in the Con A model of murine hepatitis (Chang et al., 2006) . However, it is difficult to interpret the results of these studies because it is established that partial JNK deficiency results in adaptation and a gain-of-function phenotype caused by the remaining JNK isoforms (Jaeschke et al., 2006) .
Here we report the analysis of compound mutation of the two ubiquitously expressed genes that encode JNK. The absence of a requirement of JNK for TNF-a-stimulated hepatocyte apoptosis is consistent with our previous analysis of TNF-a-stimulated JNK1/2-deficient primary murine embryo fibroblasts , and is also consistent with our finding that apoptosis caused by a different death receptor ligand (FasL) is also JNK independent (Tournier et al., 2000) .
JNK Is Required for TNF-a Expression
The expression of TNF-a is regulated at multiple steps, including Tnfa gene transcription, Tnfa mRNA stability, and Tnfa mRNA translation (Han et al., 1990; Tsai et al., 2000) . The ERK and p38 MAP pathways are implicated in the regulation of Tnfa mRNA stability and translation (Dumitru et al., 2000; Hitti et al., 2006) and it is established that JNK plays an important role in Tnfa gene transcription . The Tnfa gene contains JNK-responsive promoter elements that are required for normal Tnfa gene expression, including a divergent AP1 site that selectively binds heterodimeric complexes of ATF2 and c-Jun (Tsai et al., 2000) . JNK can phosphorylate ATF2 and c-Jun within the NH 2 -terminal transcription activation domain leading to increased transcription activity (Davis, 2000) . Indeed, JNK1/2-deficient fibroblasts exhibit a severe defect in Tnfa mRNA expression and JNK1/2-deficient macrophages and T cells express profoundly reduced amounts of TNF-a in the culture medium ( Figures 6B and S4 ).
Role of JNK in Immune Cells in the Liver JNK is required for the production of TNF-a by hematopoietic cells for the development of hepatitis. Because membranebound TNF-a, but not soluble TNF-a, is required for Con A-induced hepatitis (Kusters et al., 1997) , it is likely that the hematopoietic cells that are the source of JNK-dependent TNF-a expression include resident inflammatory cells in the liver (e.g., Kupffer cells and NKT cells).
The liver represents the major reservoir of NKT cells in the body, and these cells are critically important for Con A-induced hepatitis (Kaneko et al., 2000; Takeda et al., 2000; Tiegs et al., 1992) . Indeed, NKT-cell-mediated expression of TNF-a, IFN-g, and IL-4 have been implicated in Con A-induced hepatitis (Kusters et al., 1996 (Kusters et al., , 1997 Tagawa et al., 1998) . Interestingly, JNK deficiency causes major defects in the Con A-induced expression of these cytokines in serum (Figure 2) . Infiltration of the liver by neutrophils and eosinophils after Con A treatment (Bonder et al., 2004; Hatada et al., 2005; Jaruga et al., 2003; Louis et al., 2002) and the production of superoxide by Kupffer cells (Morita et al., 2003) might also contribute to hepatitis development. Nevertheless, TNF-a expression by NKT cells is critically required for Con A-induced hepatitis. Thus, Con A causes greatly reduced hepatitis in Tnfa À/À mice, Tnfr1 À/À mice, and Tnfr2 
Conclusions
The results of this study demonstrate that JNK plays a critical role in mouse models of TNF-a-dependent hepatitis. It is possible that under some specific conditions, JNK might influence cFLIP degradation (Chang et al., 2006) or ROS production (Ventura et al., 2004 ) during TNF-a-stimulated cell death. However, JNK is not required for TNF-a-mediated death of hepatocytes in models of fulminant hepatitis. In contrast, JNK is essential for the expression of TNF-a by hematopoietic cells that promote hepatitis.
EXPERIMENTAL PROCEDURES Mice
We have previously described Jnk1 À/À mice (Dong et al., 1998) , Jnk2 À/À mice , and Jnk1 f/f mice (Das et al., 2007) . The JNK knockout mice were maintained on a C57BL/6J mouse strain background (backcrossed ten generations). Alb-Cre mice (Postic et al., 1999) , Mx1-Cre mice (Kuhn et al., 1995) , B6.SJL mice, and C57BL/6J mice were obtained from The Jackson Labs. The mice were housed in a facility accredited by the American Association for Laboratory Animal Care (AALAC). Deletion of floxed alleles in Mx1-Cre mice was performed by treatment of 4-week-old mice with 20 mg/g poly-IC (Mikkola et al., 2003) followed by recovery (4 weeks). Genomic DNA was examined using PCR amplimers (5 0 -CTCAGGAAGAAAGGGCTTATTTC-3 (Das et al., 2007) . Radiation chimeras using congenic C57BL/6J and B6.SJL mice were generated by exposure of recipient mice to two doses of ionizing radiation (525 Gy) and reconstitution of the mice with 10 7 donor bone marrow cells by injection into the tail vein. We examined three models of murine hepatitis using intravenous injection of: (a) 25 mg/kg Con A (Sigma); (b) 35 mg/kg E. coli 0111:B LPS (Sigma) plus 1 g/kg N-acetyl-galactosamine (GalN) (Sigma); and (c) 20 mg/ kg TNF-a (R&D Systems) plus 1 g/kg GalN. The animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical School.
Serum Analysis
Alanine transaminase (ALT) and aspartate aminotransferase (AST) activity in serum was measured using the ALT and AST Reagent kit (Pointe Scientific) with a Tecan Sapphire microplate reader (Tecan Trading AG). The serum concentration of cytokines was measured by multiplexed enzyme-linked immunosorbent assay (ELISA) using a Luminex 200 instrument (Millipore).
Biochemical Analysis
Immunoblot analysis was performed by probing with antibodies to ERK1/2 (Santa Cruz), JNK1/2 (PharMingen), cFLIP (Alexis), cleaved PARP, cleaved caspase 3 (Cell Signaling), and a-tubulin (Sigma). The amount of total and phospho-JNK1/2, c-Jun, ERK1/2, p38 MAPK, and AKT in tissue extracts was measured by multiplexed ELISA using a Luminex 200 instrument (Millipore). The expression of mRNA was examined by quantitative RT-PCR analysis using a 7500 Fast Real Time PCR machine. Taqman assays (Applied Biosystems).
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